Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has unveiled significant progress in its suzetrigine pain program, potentially introducing the first new class of medication for acute and neuropathic pain in over twenty…
Six-Year Efficacy of Novartis Kesimpta® in Relapsing MS Treatment-Naïve Patients
Novartis has revealed findings from the ALITHIOS open-label extension study, demonstrating the sustained efficacy of continuous Kesimpta® (ofatumumab) treatment for up to six years in individuals recently diagnosed with relapsing…
FDA Greenlights Alecensa by Roche for Early-Stage ALK-Positive Lung Cancer
Roche Receives FDA Approval for Alecensa as Adjuvant Therapy in ALK-Positive Early-Stage Lung Cancer Roche has announced that the U.S. Food and Drug Administration (FDA) has granted approval for Alecensa®…
Positive Outcomes in Giant Cell Arteritis Patients from Phase 3 SELECT-GCA Trial of Upadacitinib (RINVOQ®)
AbbVie (NYSE: ABBV) has announced encouraging findings from its Phase 3 trial, SELECT-GCA, showcasing positive top-line results. The trial, conducted across multiple centers, employed a randomized, double-blind, placebo-controlled design. It…
Building climate-resilient health clinics
On July 4, 2023, Lafayette, Louisiana experienced a seemingly typical Fourth of July, with kids playing soccer, families preparing for barbecues, and the familiar Louisiana heat enveloping the town. However,…
NEXT GENERATION PEPTIDE DRUGS FAVOR SYNTHETIC, NOT RECOMBINANT MANUFACTURING
Peptide manufacturing for commercial-scale production primarily employs two main methodologies: synthetic and recombinant. Each method presents unique advantages and challenges, crucial for stakeholders in the pharmaceutical industry to consider when…
Supporting Save the Children Finland: Orion’s Donation Ensures No Child or Young Person Copes Alone
The rising cost of living compounds the difficulties faced by low-income families with children, creating an urgent need for support, says Heidi Herranen, Coordinator of Save the Children Finland’s Fuel…
Cerevel Therapeutics Reports Favorable Topline Findings in Phase 3 Adjunctive Study of Tavapadon for Parkinson’s Disease Patients
Cerevel Therapeutics (Nasdaq: CERE) has released encouraging findings from its pivotal Phase 3 TEMPO-3 trial for tavapadon, a unique D1/D5 receptor partial agonist investigated as a once-daily treatment for Parkinson’s…
WHO Grants Prequalification to Innovative Oral Cholera Vaccine
A new oral vaccine for cholera has received prequalification by the World Health Organization (WHO) on 12 April. The inactivated oral vaccine Euvichol-S has a similar efficacy to existing vaccines…
Debut of WHO’s Patient Safety Rights Charter Marks Milestone in Healthcare
Today marked a significant milestone in healthcare as the World Health Organization (WHO) unveiled the Patient Safety Rights Charter during the Global Ministerial Summit on Patient Safety. This groundbreaking Charter,…
Updated Terminology for Airborne Pathogens Released by Leading Health Agencies
In collaboration with public health agencies and experts worldwide, the World Health Organization (WHO) has released a comprehensive report introducing updated terminology for pathogens transmitted through the air. The report,…
NEXT GENERATION PEPTIDE DRUGS FAVOR SYNTHETIC, NOT RECOMBINANT MANUFACTURING
The advent of new drugs targeting diabetes, obesity, and cardiovascular diseases has sparked a surge in the demand for polypeptide manufacturing. This surge, in turn, has propelled an industrial intensification…